TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
39.17
-0.03 (-0.08%)
May 28, 2026, 1:00 PM EDT - Market open
TG Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, TG Therapeutics stock has a consensus rating of "Buy" and an average price target of $48. The average 1-year stock price forecast is 22.54% higher than the current stock price, while the lowest is $17 (-56.60%) and the highest is $70 (+78.71%).
Price Target: $48 (+22.54%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for TG Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $70 | Buy | Maintains | $70 | +78.71% | May 27, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $40 → $42 | Hold | Maintains | $40 → $42 | +7.22% | May 8, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $50 | Buy | Maintains | $50 | +27.65% | May 6, 2026 |
| Bank of America Securities | Bank of America Securities | Sell Reiterates $15 | Sell | Reiterates | $15 | -61.71% | Apr 8, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $49 → $46 | Buy | Maintains | $49 → $46 | +17.44% | Feb 2, 2026 |
Financial Forecast
Revenue This Year
954.25M
from 616.29M
Increased by 54.84%
Revenue Next Year
1.24B
from 954.25M
Increased by 30.36%
EPS This Year
1.50
from 2.77
Decreased by -45.82%
EPS Next Year
2.65
from 1.50
Increased by 76.41%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.0B | 1.4B | ||||||
| Avg | 954.3M | 1.2B | ||||||
| Low | 871.2M | 1.0B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 64.7% | 51.6% | ||||||
| Avg | 54.8% | 30.4% | ||||||
| Low | 41.4% | 9.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.77 | 3.76 | |||
| Avg | 1.50 | 2.65 | |||
| Low | 1.08 | 1.52 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -35.9% | 150.5% | |||
| Avg | -45.8% | 76.4% | |||
| Low | -61.1% | 1.2% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.